DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

/in

Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company […]

Read more

Destiny Pharma announces start of a new XF-73 research programme

/in

Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis Oral Mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2m cancer patients every year Brighton, United Kingdom – 05 July 2022 – Destiny Pharma plc (AIM: DEST), […]

Read more

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

/in

Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead […]

Read more

eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine

/in

A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine  CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]

Read more

Versameb to Present during World Continence Week 2022

/in

Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence Raising awareness of the high unmet medical need of patients Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, […]

Read more
© Optimum Strategic Communications.